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要旨 
論文題名 
ポジトロン断層法イメージングに使用する金属放射性薬剤の開発について：亜
鉛 63の製造とガリウム標識プローブの分子設計 
[背景] ポジトロン断層法「PET」は、陽電子放出核種から放出された陽電子と陰電子
とが衝突して生成する 2 個の消滅ガンマ線を対向に設置された検出器で同時に検出す
ることにより，優れた解像度と高い感度および定量性を併せ持つ分子イメージング技
術である。PET では陽電子放出核種で標識された薬剤（プローブ）を人体に投与し、
目的組織に集積したプローブから発生された消滅ガンマ線を検出することにより、分
子・細胞レベルにおける生物学的なプロセスを in vivo で可視化、計測する。亜鉛は生
体関連プロセスに関わる必須金属であり、その陽電子放出核種は、亜鉛の生体内プロ
セスを直接評価できるため、高い関心を集めている。しかし、利用可能な放射性亜鉛
には 62Znと 65Znがあるが、これらの放射性核種は分子イメージングで最適な性質を有
していない。一方、ゲルマニウム/ガリウムジェネレータから溶出可能なガリウム-68
「68Ga」はサイクロトロンを必要としない陽電子放出核種として関心を集めている。
68Ga では標的分子認識素子を持つ放射性プローブを調整するために様々な二官能性キ
レートが開発されている。その一つに、分子内に複数分子の標的分子認識素子を導入
可能な 1,4,7-triazacyclononane -1,4,7-tris-(glutaric acid) (NOTGA)がある。NOTGAにはジ
アステレオマーを含む構造異性体が生成するが、これまでにそれらの詳細な評価は行
われていない。そこで、本研究では分子イメージングに適した性質を持つ 63Zn の新た
な製造および精製システムの開発と、多量体ガリウム放射性薬剤用の 1,4,7-
triazacyclononane -1,4,7-tris-(glutaric acid) (NOTGA)ジアステレオマーの合成およびそれ
らの評価を行った。 
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陽電子を放出する亜鉛 63の製造に関する基礎的研究 
「背景」陽電子を放出する亜鉛には亜鉛 62「62Zn」、亜鉛 63「63Zn」および亜鉛 65
「65Zn」がある。62Zn は半減期 9.3 hで陽電子放出核種である 62Cu「T1/2 = 9.7 min」に
壊変し、また 65Zn は 243.9日と非常に長い半減期を有する。一方、63Znは半減期 38.5
分で、安定同位体 63Cu に壊変することから、63Zn は核医学イメージングにおいてより
望ましい性質を有する。これまでの 62Znおよび 65Znを用いた報告から 63Znは腫瘍また
はすい臓疾患のイメージングに有用と考えられる。 
「方法と結果」天然由来銅ターゲット「63Cu: 69.17% ・65Cu: 30.83%」に 13.5 MeVの陽
子を照射し、63Zn を製造した。その後、陽イオン交換カラム「0.05 N HCl-85%アセト
ン」により精製し総収率 169  30 MBq/A·hで 63Znを得た。放射化学的純度は 99%以
上で、不純物として 65Zn のみ観察された。一方、照射 1.6 時間後の比放射能は 29.4 
GBq/molであった。ターゲットである Cuの残存量は 0.04 g/g 以下であった。ラット
を用いた PET撮像では 63Znの体内動態は以前報告された 65Znの動態と一致し、すい臓
に高い集積を示し、63Znの分子イメージングへの応用の可能性が認められた。 
「考察」63Zn の製造および精製法を確立した。その方法は迅速かつ直接的であり高い
化学的および放射科学的純度で 63Zn を得た。PET 画像において亜鉛のすい臓への特徴
的な集積が観察された。本成果により PETの分子イメージングを目的とする 63Znの利
用が可能となった。 
多量体ガリウム放射性薬剤としての 1,4,7-triazacyclononane-1,4,7-tris-(glutaric 
acid) (NOTGA)のジアステレオマーの合成と検討 
「背景」ガリウム-68「68Ga」は半減期 67.7 分であることから速やかな薬物動態を示す
低分子化合物の標識に有用である。一方、標識プローブの設計においては、標的分子
認識素子を分子内に複数分子持つ多価化合物は、標的分子認識素子を一分子しか持た
ない一価化合物に比べ、高い結合力を有し、これは多価効果として知られている。二
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官能性キレートである NOTGAは多量体の 68Ga放射性薬剤を調整するために開発され
た。NOTGA は(R,S) -bromoglutaric acid 1-tert-butyl ester 5-benzyl ester を用いて 1,4,7-
triazacyclononane の窒素にアルキル化することでジアステレオマーである RRR/SSS と
RRS/SSR の 2 つの鏡像異性体を生成する。そこで、これらのジアステレオマーの性質
を評価するために，それぞれの NOTGA-tBu3キレート前駆体または triethylene glycol リ
ンカー「TEG」を含む RGD ペプチド結合体を合成し、67Ga による標識、および 67Ga
標識体の安定性、Integrin v3の結合親和性および体内動態を比較した。 
「方法と結果」NOTGAの RRR/SSSと RRS/SSRのジアステレオマーを 69%と 17%の合
成収率で得た。67Ga による標識反応を配位子濃度 10 μM、室温において検討した結果， 
RRS/SSRは pH依存性を示さなかったが、RRR/SSSは pH依存的に変化し pH 5が最適で
あった。標識溶液 pH 5ではいずれのジアステレオマー錯体も、10分以内に、放射化学
的収率 95％以上で得られた。いずれのジアステレオマー錯体も apo-Transferrin 溶液中
で安定に存在することを確認し、標的へ同程度の結合親和性を認めた。正常マウス実
験において各ジアステレオマー錯体は同様の体内動態を示し、いずれも腎臓排泄であ
った。また、U87MG 細胞を移植した担癌モデルマウスを用いた検討では，いずれも腫
瘍に対して同程度の集積を認め、SPECT/CT画像として鮮明な画像を与えた。 
「考察」本研究成果により、NOTGA-(TEG-RGD)3誘導体のジアステレオマーの構造学
的な相違は 67Ga 標識反応、または生物学的な性質に有意な影響を与えず、混合ジアス
テレオマー放射性薬剤の使用が可能であることを示した。しかしながら、標的分子認
識素子の特異的な性質と細胞でのレセプター発現レベルや薬物動態修飾リンカーなど
はジアステレオマーの構造学的な相違による分子プローブのリガンド－レセプターの
相互作用または薬物動態に影響する可能性があることから、異なる標的分子認識素子
に NOTGA を応用する際には誘導体の調製または化学的なおよび生物学的性質を調べ
ることが重要であると考えられる。 
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「総括」陽電子放出核種である 63Zn と 68Gaの純粋な NOTGAジアステレオマー分子
プローブは分子イメージングにおいて新規 PET 放射性薬剤の開発に寄与すると期待で
きる。 
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Preface 
In recent years, a greater understanding between disease pathogenesis and molecular alterations 
at cellular levels has promoted the discovery of molecules able to target these alterations.(1, 2) 
Molecular Imaging aims to use these “targeting molecules” for the visualization, 
characterization, and measurement of biological processes at the molecular and cellular 
levels.(3) The relevance of this discipline is not simply to study the biology underneath a 
disease, but to do it in a personalized approach; allowing personalized medical care based on 
individual specificities. In cancer patient management, one of the leading causes of dead 
worldwide, the diagnosis and staging of tumors, as well as, assessment of therapeutics targets, 
monitoring therapy and prognosis evaluation can be performed.(1, 2) Molecular imaging can be 
also applied to the process of new drug discovery or in basic science, to the discovery of new 
targets for diagnosis and treatment.  
Radiotracer imaging by Positron Emission Tomography (PET) is one of the techniques used in 
molecular imaging, due to the high quantification and resolution properties of this imaging 
modality.(1, 4) PET imaging is based on the detection of the anti-parallel 511 keV gamma rays 
emitted from the annihilation of positrons with surrounding electrons (Figure 1 A) by detectors 
arranged in a ring around the subject (Figure 1 B). Only two photons detected in coincidence 
(10 – 20 ns) are registered, being unnecessary physical collimation to block scattered photons 
not perpendicular to the detector surface. Due to this “electronic” collimation PET will therefore 
be much more sensitive (1 – 2 orders higher) than other radiotracer based modalities, such as 
Single Photon Emission Computed Tomography (SPECT). The number of coincidences 
registered by all possible detector pairs along their respective axis provides an estimation of the 
number and position of the positron-emitting nuclides, hence a quantitative map of the 
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radiopharmaceutical concentration over time throughout the living human being.(1) 
 
Figure 1. PET imaging basic principles. (A) The movement of the positron before annihilating 
with an electron, with emission of two 511 keV photons opposite to each other; and (B) a 
scheme depicting a PET camera with the acquisition system. Only coincident photons and not 
scattered are registered  
PET radioisotopes are artificially produced with high specific activities in cyclotrons, as result 
of the nuclear reaction induced upon the irradiation of a target element with protons, deuterons, 
etc. The traditional PET isotopes are fluorine-18 (18F), carbon-11 (11C), nitrogen-13 (13N) and 
oxygen-15 (15O) (Table 1). 11C, 13N and 15O are considered “biological” positron-emitting 
isotopes, since they are chemical elements normally found in biological substrates. By far 18F is 
the most used among them, partly because its ideal decay properties, i.e. high positron 
abundance and low positron energy; and the success of 2-deoxy-2-[18F]fluoroglucose, an FDA 
approved radiopharmaceutical to study drug metabolism in lung, heart, brain, and localization of 
tumors.  
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Table 1 Decay data and production routes of commonly used PET radioisotopes (1, 5, 6) 
Nuclide Decay Mode (%) T1/2 E+ keV (%)
a Nuclear reaction for 
production 
11C +(99.8) 20.36 min 960.4 (99.80) 14N(p,α)11C 
13N +(100) 9.97 min 1199 (99.80) 16O(p,α)13N 
15O +(100) 2.04 min 1732 (99.90) 15N(p,n)15O 
14N(d,n)15O 
18F +(100) 109.8 min 633.5 (96.70) 18O(p,n)18F 
64Cu +(17.6) 
EC(43.9) 
-(38.5) 
12.7 h 653.0 (17.60) 64Ni(p,n)64Cu 
68Ga +(89.1) 
EC(10.9) 
67.7 min 1899 (87.94) 68Ge/68Ga Generator 
 aMean + energy (total + intensity) 
One important aspect in the progress of molecular imaging field is the development of improved 
imaging probes. In PET-based radiopharmaceuticals this is translated, among others, into the 
production of novel radioisotopes with more desirable nuclear or chemical properties to match 
an intended molecular process.  
In this sense, there are essential trace elements in the body, such as zinc, whose radioactive 
isotopes could be directly used to study biofunctions or molecular interactions where the metal 
plays an important role, a subject not exploited yet in molecular imaging. They can be thought 
as the metallic version of the “biological” radioisotopes. Zinc is a metal involved in numerous 
biological processes in the body (7) and among the useful radioactive zincs (62Zn, 63Zn, 65Zn), 
63Zn possesses the most appropriate nuclear properties for PET imaging. However, the 
radionuclide was not available for molecular imaging purposes due to the lack of production 
and purification methods.  
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On the other hand, alternative positron-emitting radionuclides can be also obtained via 
generators. A representative example is the metallic radioisotope gallium-68 (T1/2 = 67.7 min) 
which is available from 68Ge/68Ga generators. 68Ga radiopharmacy is cyclotron-independent and 
allows the development of cold, freeze-dried kits that can be conveniently labeled similar to the 
case of 99Mo/99mTc-generators, at the workhorse in nuclear medicine. The attention gained by 
68Ga is evidenced by more than 50 radiopharmaceuticals enlisted in the Molecular Imaging and 
Contrast Agent Database (MICAD) (8) and the clinical success of 68Ga-DOTATOC for imaging 
somatostatine receptors in neuroendocrine tumors.(9, 10) 
One major advantage of metallic radioisotopes like 68Ga is their simpler radiolabeling, governed 
by their coordination chemistry. It allows the development of bifunctional chelators (BFC), 
which are in essence chelators equipped with functional groups for both, conjugation of a 
biomolecule of interest and coordination of the metal cation. Therefore, a metal containing 
molecular probe consists of a radionuclide wrapped by the BFC, the targeting molecule and 
additionally a pharmacokinetic modifier (PkM) linker is sometimes included (Figure 2).(11) 
Novel BFCs for gallium that improve aspects of molecular design such as, conjugation of 
biomolecules, radiolabeling or implementing innovative targeting strategies to increase probe 
avidity, have been developed.(12-15) One example is 1,4,7-triazacyclononane-1,4,7-tris-
(glutaric acid) (NOTGA). This BFC possesses a 1,4,7-triazacyclononane (TACN) core structure 
with three glutaric acid pendant arms; and it was designed to allow multiple conjugation of 
targeting molecules as a way to exert the multivalent effect,(16, 17) a targeting strategy used in 
receptor-based imaging for maximizing binding capabilities.(11, 18-21) One peculiarity in 
NOTGA is the presence of three chiral centers located at the alpha position of each glutaric acid 
moieties, leading to the formation of two diastereomeric pairs of enantiomers. However, their 
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isolation and the influence their structural differences, which might affect the stability, 
radiochemistry, target affinity, pharmacokinetics and in vivo targeting properties, have not been 
study yet.  
 
Figure 2. Molecular probe design of a metal-based radiopharmaceutical. PkM (Pharmacokinetic 
Modifier) 
With all above in mind, it is the intention of the present thesis to tackle two important aspects of 
the development of PET-based radiopharmaceuticals: first, the radioisotope production, 
materialized in the development of a method for the production and purification of the metallic 
positron emitting radionuclide zinc-63; and second, the molecular probe design, exemplified in 
the synthesis and evaluation of diastereomers of NOTGA for the preparation of multimeric 
radiopharmaceuticals of gallium. 
The first topic is addressed in Chapter 1 entitled “Production and purification of the positron 
emitter zinc-63”. The Introduction section makes a summary of the role of zinc in the human 
body and the applications that radioactive zinc has found so far. It also presents the advantages 
of 63Zn over the analogues 62Zn and 65Zn and the irradiation of copper targets with protons as the 
most convenient 63Zn production route. Materials and methods section gives details of the 
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irradiation protocol, the purification system based on cation exchange chromatography, 
including a detailed scheme, and the analytical methods used to assess the purity of the 63Zn 
final solutions. Issues such as, proton energy selection, copper target thickness and its impact on 
the following purification step are addressed in 63Zn production of the Results and Discussion. 
In the same section, the efficacy of the purification method to save elution time to avoid decay 
of the 63Zn product, and to provide high purity final product is analyzed in Radiochemical 
processing of 63Zn. Further, the applicability of the 63Zn was estimated in a PET imaging study. 
The chapter finishes with the partial conclusions. 
Chapter 2 presents the “Synthesis and evaluation of diastereoisomers of 1,4,7-
triazacyclononane-1,4,7-tris-(glutaric acid) (NOTGA) for multimeric radiopharmaceuticals of 
gallium”. Introduction section makes a brief summary of the nuclear properties and coordination 
chemistry of gallium radioisotopes important to imaging, aspects related to TACN-based BFC 
designed for multi-attachment of biomolecules and the formation of stereoisomers are also 
revised. The possibility of preparation of diastereomerically pure NOTGA radiopharmaceuticals 
is postulated and a RGD peptide molecular probe is formulated to address the problem. The 
synthetic procedures and other in vitro and in vivo experiments protocols are presented in 
Materials and Methods. A whole section devoted to Results includes, among others, the 
isolation of isomers of NOTGA, 67Ga radiolabeling, stability, in vitro affinity for integrin v3, 
and animal experiments. The results are analyzed and discussed in relation to the existing 
international knowledge in the Discussion section. Conclusions to this chapter are also given.  
General Conclusions will integrate the achievements of the thesis from a global point of view 
and references will be gathered in the Bibliography section.  
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Chapter 1.                                                                                  
Production and Purification of the Positron Emitter    
Zinc-63 
1.1. Introduction 
Zinc is one of the essential trace minerals in the body, and is required for the metabolic 
activity of more than 300 enzymes. It is also involved in protein, nucleic acid, carbohydrate, and 
lipid metabolism, as well as in the control of gene transcription and other fundamental 
biological processes.(7) Zinc deficiency and perturbations of zinc metabolism are now 
recognized as factors in the pathogenesis of several chronic diseases.(22)  
Although the potential use of 63Zn-EDTA was reported in 1974,(23) the application of 
radioactive zinc for imaging purposes has been limited to 62Zn and 65Zn. They have been used 
for preparing pancreas-seeking radiopharmaceuticals,(24-27) labeling an anti-cancer agent, (28, 
29) and brain tumor imaging.(30-34) 
Table 1.1 Decay data of zinc radioisotopes (6) 
Parent Nucleus Decay mode T1/2 E+ keV (%)a Daughter Nucleus
 EC, + 9.26  h 259 (8.40)  
 EC, + 38.47 min 992 (92.7)  
 EC, + 243.93 d 143 (1.42)  
 aMean + energy (total + intensity) 
 
Zn6230 Cu
62
29
Zn6330 Cu
63
29
Zn6530 Cu
65
29
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However, these zinc radioisotopes present some drawbacks as radionuclides for PET 
imaging. 62Zn is a positron emitter with a half-life of 9.26 h, which decays to another positron 
emitter, 62Cu, with 9.7 min of half-life. This constitutes a source of non-isotopic radionuclidic 
impurity. The long half-life of 65Zn, on the other hand, would result in unacceptable radiation 
exposure to patients, which significantly hinders its clinical application (Table 1.1). 
Furthermore, the positron emission intensity of both radioisotopes is rather low. Conversely, 
63Zn decays to the stable 63Cu with a half-life of 38.47 min and has high positron abundance 
(Table 1.1). Such nuclear properties render 63Zn an attractive radionuclide for molecular 
imaging to better understand the role played by the metal in the body through PET imaging. 
However, the application of 63Zn has been unexplored, because of the lack of methods for the 
production and purification of non-carrier added (n.c.a) 63Zn. 
63Zn can be produced by irradiating natural copper with protons through the natCu(p,n)63Zn 
nuclear reaction that exhibits high cross section values at low proton energies.(35) Although the 
60Ni(α,n)63Zn nuclear reaction exhibits comparable cross sections,(36) the coproduction of 62Zn 
is inevitable, making its application difficult. 63Zn can also be produced from the irradiation of 
natural zinc with neutrons thorough the 64Zn(n,2n)63Zn;(23) however, the reaction produces 63Zn 
in a carrier-added form. In this study, the production of 63Zn through the irradiation of natural 
copper targets with proton beams, its subsequent purification by ion exchange chromatography, 
as well as a pilot PET imaging study is presented.  
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1.2. Materials and methods 
1.2.1. General 
Copper foils (100 μm in thickness, 99.99 % purity) were purchased from Fuchikawa Rare 
Metal Co. (Tokyo, Japan). Analytical grade ion exchange resin (AG 50W-X8, H+ form, 100-200 
mesh) was obtained from Bio-Rad Laboratories, Inc (Tokyo, Japan). Reagents used in standard 
productions were analytical grade from Wako Pure Chemical Industries, Ltd (Osaka, Japan) and 
used without further purification. Water was purified using a Milli-Q purification system. To 
reduce the amount of metal impurity ultra-pure grade conc. Nitric acid, conc. HCl and water 
were purchased from Wako Chemicals and; acetone was purchased from Kanto Chemical Co., 
Inc (Tokyo). Proton energy calculations were performed using the software SRIM.exe 2008-3 
(37) or stopping power formulas.(38) The primary beam energy (14 MeV nominal) was checked 
using the ratio 65Zn/63Zn determined experimentally from the natCu(p,x)63,65Zn nuclear reactions 
in a copper foil of 20 m thickness (39) (13.93  0.12 MeV experimental). Cross-section data 
was taken from IAEA TECDOC 1211.(35) 
1.2.2. Production of 63Zn via natCu(p,n)63Zn reaction 
The irradiations were carried out using protons of 14 MeV from the AVF-930 cyclotron of 
the National Institute of Radiological Sciences of Japan, at beam intensities of 0.5 – 8 μA for 
0.5 – 1.5 h. A stack of 1.9 cm in diameter was arranged using an aluminum foil of 70 μm 
thickness to degrade the energy from 14 MeV to 13.5 MeV and the copper target of 100 μm 
thickness (13.5  11.4 MeV). After irradiation, the target holder was removed from the 
irradiation port and transferred to a shielded hot cell where all the operations were performed 
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remotely.(40) 
1.2.3. Purification of 63Zn from the Cu target 
The purification of 63Zn was carried out using the apparatus shown in Figure 1.1. The 
irradiated Cu foil was dropped inside the dissolution vessel using mechanical arms. The HNO3 
(1.5 mL) was added to the vessel from the A Line. After complete dissolution of the foil, water 
(15 mL) was added from the B Line and the solution was bubbled with air. The solution was 
loaded onto a cation exchange resin column (AG 50W-X8, H+ form, 1 cm I. D. × 40 cm, 
preconditioned with water) using a peristaltic pump. The column was then washed with 10 mL 
of water (from the D line). Lastly, 63Zn was eluted with a mixture of 0.05 N HCl – 85% acetone 
solution (prepared by mixing 0.33 M HCl and acetone at 1:5.7 v/v ratio) from the C line at a 
flow rate of approximately 3.5 mL/min. The eluents were monitored using the radiation sensor 
(RS). Radioactive fraction was collected and concentrated to dryness to remove HCl using a 
rotary evaporator. After the radioactive solution was evaporated to dryness, the residue was re-
dissolved in 5 – 10 mL of H2O or saline. 
1.1.1. Analysis of final product solutions 
The radioactivity was determined both destructively and non-destructively by standard 
gamma-ray spectrometry using a HpGe detector Gx1020 (4098 channels, 0.9 keV/channel, 34 – 
3643 keV) manufactured by Canberra Industries, Inc, CT, USA coupled to the acquisition 
system RZMCA 1.1.0.3 (Laboratory Equipment Corporation, Ibaraki, Japan) as well as a dose 
calibrator (ICG-3, ALOKA CO., LTD, Tokyo), which was cross-calibrated with the HpGe 
detector. The energy and efficiency calibration of the HpGe system was done using a 152Eu 
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certified calibration source obtained from Japan Radioisotope Association (Tokyo); and 137Cs 
and 60Co standard sources from QSA Global Inc. (Burlington, USA) (error < 3 %). Gamma ray 
energies and intensities for calibration were taken from the Nudat database.(6) The detector-
source distance was kept high enough to avoid summation of the pulses originating from 
cascade processes and dead times of less than 5 %. 
 
Figure 1.1. Apparatus used for the production of 63Zn from the copper target. (RS: Radiation 
sensor) 
The final 63Zn solutions were analyzed also by high performance ion exchange 
chromatography coupled to a UV–Vis detector (2475, Waters Corporation, Milford, MA, USA) 
and a NaI(Tl) radioactivity detector (Ohyo Koken Kogyo Co; LTD, Tokyo). The metal analysis 
was performed by ion chromatography with post column method. Samples were analyzed on a 
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column (IonPac CS5A, 4 mm I.D. × 250 mm; Dionex K.K., Osaka) equipped with a guard 
column (IonPac CG5A, 4 mm I.D. × 50 mm, Dionex K.K., Osaka) with mobile phase of diluted 
MetPac PDCA (Dionex K.K, Osaka) (MetPac PDCA : H2O = 1 : 5) at a flow rate of 1.2 mL/min. 
MetPac PDCA represents 7 mM of pyridine-2,6-dicarboxylic acid, 66 mM of potassium 
hydroxide, 5.6 mM of potassium sulfate and 74 mm of formic acid. The eluents from the 
column were mixed with a post column reagent, 4-(2-pyridylazo) resorcinol (PAR) in MetPac 
eluent (0.06 g/L), at a flow rate of 0.6 mL/min. MetPac represents 1 M of 2-
dimethylaminoethanol, 0.5 M of ammonium hydroxide and 0.3 M of sodium bicarbonate 
solution The mixture was monitored at 530 nm. The lower limits of detection of the elements 
were 0.020 g/g (Fe), 0.125 g/g (Ni), 0.020 g/g (Co), 0.019 g/g (Cu) and 0.018 g/g (Zn). 
1.1.2. Small-animal PET scanning 
Male Wistar rats (8 weeks old) were obtained from Japan SLC (Shizuoka, Japan). The 
animal experimental procedures were approved by the Animal Ethics Committee of the National 
Institute of Radiological Sciences. A chest/abdominal PET scan was performed using small-
animal PET scanner, InveonTM (Siemens Medical Solutions USA, Knoxville, TN), which 
provides 159 transaxial slices 0.796 mm (center-to-center) apart, a 10 cm transaxial field of 
view (FOV), and a 12.7 cm axial FOV.(41) Prior to the scan, the rat was anesthetized with 5% 
(v/v) isoflurane, and maintained thereafter by 1–2% (v/v) isoflurane. After transmission scans 
for attenuation using a Cobalt-57 point source, emission scan was acquired for 60 min after 
intravenous injection of [63Zn]ZnCl2 (16 MBq, 0.3 mL). All list-mode acquisition data were 
sorted into 3-dimensional sinograms, which were then Fourier rebinned into 2-dimensional 
sinograms (frames × min; 4 × 1, 8 × 2, 8 × 5). Dynamic images were reconstructed with filtered 
back-projection using Hunning’s filter, and a Nyquist cutoff of 0.5 cycle/pixel. 
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1.3. Results and Discussion 
1.1.3. 63Zn production  
63Zn can be formed from natural copper (63Cu, 69.2%; 65Cu, 30.8%) via two nuclear 
reactions: 63Cu(p,n)63Zn with a threshold energy of Eth = 4.2 MeV, and 65Cu(p,3n)63Zn, with Eth 
= 22.3 MeV. The highest cross section values (probability of the reaction to occur) of the 
63/65Cu(p,n)63Zn reaction are attained at a proton energy range between 16 to 6.5 MeV with a 
maximum at proton energy of 12.55 MeV. Unfortunately, within this useful energy region, both 
62Zn and 65Zn are also produced (Figure 1.2). Hence, careful selection of the initial proton 
energy was needed in order to minimize impurities. The generation of undesired 62Zn was 
completely avoided at proton energy levels below 13.47 MeV, the threshold energy of the 
63Cu(p,2n)62Zn reaction.  
The yield of 63Zn increases as incident energy range increases using thick targets. However, 
the use of thick copper targets requires larger columns in the purification process, which result 
in longer purification times to remove the target. Therefore, a favorable balance between the 
target thickness and purification time (i.e. yields at the end of bombardment (EOB) and at the 
end of processing) is necessary. The consideration led us to select a target thickness of 100 μm 
for an energy range from 13.5 to 11.4 MeV (Figure 1.2), thereby covering the highest cross-
section values for a theoretical yield of 1.87 GBq/μA·h. This is a production parameter that is 
calculated using the relationship:  integrated over the energy 
range and expressed in . The product of the number of target atoms (Natoms), the number 
of incident protons (Nproton) and the cross-section () gives the number of product atoms formed, 
)(ENNY protonatoms  


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
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that multiplied by the disintegration constant ( ) gives the activity of the sample (in Bq). 
The number of protons Nproton is conveniently expressed in 1/μA·h for practical reasons. It can 
be observed that long-lived radionuclides will have low yields. Nevertheless, experimentally the 
production yield is calculated from the measured activity following the relationship: 
. Where I (in μA) is the beam intensity and T (in h) is the irradiation 
time. 
 
Figure 1.2. Reaction cross-section of zinc radioisotopes in proton irradiated copper (35) 
The experimental thick target yields determined from trial irradiations are presented in Table 
1.2. The average was 1.41  0.19 GBq/μA·h, which is 75.4 % of the predicted value and some 
deviation was observed in one of the experiments. Since the energy was found to be in 
agreement with the nominal value, factors such as variations in the current delivered by the 
cyclotron, beam alignment, uncertainty in the activity determination, etc., might affect the 
results. Irradiated targets were allowed to decay and the radioactivity was measured. Although 
2/1
2ln
T

 TeIActivityY  1
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the formation of 62Zn was completely avoided, the gamma spectrometry analysis of the copper 
targets revealed the presence of 65Zn and 64Cu impurities. The resulting yields were 91 ± 9.3 
kBq/μA·h for 65Zn and 164 kBq/μA·h for 64Cu. 65Zn is formed only from 65Cu via the 
65Cu(p,n)65Cu reaction with a threshold energy of Eth = 2.2 MeV. Meanwhile, 64Cu is formed 
from the nuclear reaction 65Cu(p,n+p)64Cu with Eth = 10.06 MeV. Thus, the use of 63Cu-enriched 
targets would allow producing 63Zn not only in high yields but also in high purities since 65Zn 
and 64Cu would be minimized. 
Table 1.2. Experimental thick target yields of 63Zna,b 
Run # A min 63Zn Yield (GBq/Ah)  % of theoretical yieldc 
1 0.50 30 1.68 89.9  
2 0.50 30 1.34 71.4  
3 1.0 30 1.37 73.0  
4 0.50 30 1.26 67.3  
a Ep= 13.5  11.4 MeV  
b Non-destructive measurements 
c Calculated yield: 1.87 GBq/Ah 
1.1.4. Radiochemical processing of 63Zn 
Due to the relatively short half-life of 63Zn (T1/2 = 38.47 min), a short and efficient 
separation process was required to minimize the loss by the decay of the product and by 
purification process. Typical procedure to separate zinc from copper through an anion exchange 
column chromatography is time-consuming (ca. 2 h), (40) as the radioactive zinc elutes after the 
elution of the copper target. To reduce purification time, a different elution system that elutes 
first the product while keeping the copper target in the column was appropriate.  
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Strelow et al. reported distribution coefficients with cation exchange resin for several metal 
ions in HCl – acetone mixture. High distribution coefficient ratio for Cu2+/Zn2+ pair of 76 is 
achieved using a 0.1 N HCl – 80% acetone.(42) Under the conditions, 63Zn was obtained in the 
first elution fractions while keeping the bulk copper target in the column. It was also 
documented that at low acid concentrations, the distribution coefficients increase as the acetone 
concentration increases, until the hydration field around the cation is weak enough to allow the 
replacement of the water dipoles in the coordination shell by chloride anions.(42) Considering 
that low acid concentration and high acetone concentration were favorable conditions for 
accelerating the evaporation step and avoiding polymerization of acetone by HCl, the elution 
conditions were also performed using a combination 0.05 N HCl – 85% acetone. Since the two 
elution conditions resulted in similar copper contents in the 63Zn fractions, the elution system 
utilizing 0.05 N HCl-85% acetone was selected to purify 63Zn from the copper target by cation 
exchange chromatography. 
In practical productions, the target foil readily dissolved in nitric acid was loaded onto the 
column without further rinsing the dissolution vessel. Radioactivity was detected between 20 
and 30 minutes after loading the metal solution and the radioactive fraction corresponding to the 
63Zn radionuclides was collected (70 – 80 mL), as shown in figure 1.3. Approximately 93.3 % 
of the loaded activity was recovered in the solution. However, losses during processing (9 % 
and 35 % of the radioactivity remained in the dissolution and evaporation vessel respectively) 
impacted the yield of HCl free 63Zn solutions. The chemical processing lasted an hour and the 
63ZnCl2 final product was ready to use at 1.6 h after EOB.  
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Figure 1.3. Radioactivity content in the effluents (expressed in arbitrary units) 
Table 1.3. Irradiation parameters, yield and purity analysis of practical production a 
Run 
# A min 
63Zn Yield 
MBq/Aha 
% 
predicteda 
Purity 
(%) 
SPA 
GBq/mola
Metal  
Impurity (g)b 
1. 8.0 60 166 44.8 99.92 29.4 Zn2+ 1.8, Cu2+ 0.2, 
Fe2+ 0.8, Co2+ 0.15  
2. 8.0 60 156 42.1 99.91 5.65 Zn2+ 7.1, Cu2+ 0.2, 
Fe2+ 1.7 
3. 6.0 90 145 39.3 99.91 4.66 Zn2+ 9.1, Cu2 + 0.1, 
Fe2+ 1.4 
4. 5.0 30 221 59.7 99.94 2.39 Zn2+ 11.8, Fe2+ 10.2
5. 5.0 30 159 43.0 99.54 1.79 Zn2+ 11.2, Cu2 + 1.2, 
Fe2+ 1.9 
a Specific activity (SPA). Referred to the End of Processing 
b Metal content per 5 mL of water/saline  
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The results of the productions are presented in Table 1.3. The average yield of the purified 
63Zn at the end of processing was 169  30 MBq/μA·h, i.e. 45.8 % of the predicted value. The 
radionuclidic purity was higher than 99%, with 65Zn being the only impurity. 64Cu was not 
detected after the purification (Figure 1.4).  
 
Figure 1.4. Gamma spectrum of the 63Zn final product. HpGe detector (30 cm of source – 
detector distance, LT 1128 sec). Gamma lines: 63Zn: 669.6 keV (8.2%), 962.1 keV (6.5%), 
1412.1 keV (0.75%); 65Zn: 1115.5 keV (50.6%) 
The HPLC-IC analyses detected Fe3+, Cu2+, Co2+ and Zn2+ (Table 1.3). The copper 
concentration could be decreased to 0.04 g/g and the only radioactive ion detected was Zn2+ 
(Figure 1.5). However, the amounts of non-radioactive zinc were relatively high at the initial 
experiments (1.42 – 1.82 g/g). The carrier zinc could come from several sources, including the 
copper target, the reagents used and contamination in the purification apparatus. When 
analytical grade reagents were changed to ultra-pure grade reagents, including water, and 
thoroughly cleaning of the production system was performed, the zinc amount decreased by a 
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factor of 5 for a specific activity of 29.4 GBq/μmol at 1.5 h EOB. Low specific activity may 
constitute a limiting factor for biological studies. Since the copper target impurities are a source 
of contaminant zinc, a reduction of the target size and use of highly pure 63Cu enriched targets 
would increase the specific activity. 
 
Figure. 1.5. Ion chromatograms of 63Zn solutions. (Fe3+: 4.25 min, Cu2+: 4.84 min, Zn2+: 6.05 
min, Co2+: 6.84 min). (AU: arbitrary units) 
1.1.5. Animal PET study 
The applicability of the presently produced 63Zn for molecular imaging was estimated in a 
PET imaging study performed 1 h after injection of [63Zn]ZnCl2 to a male Wistar rat (Figure 
1.6). Radioactivity was observed in the liver and kidneys, in good agreement with tissue 
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distribution studies previously reported using the radioisotope 65Zn.(26, 43-45) Furthermore, 
accumulation was also observed in pancreas, attributable to the utilization of the metal for 
exocrine functioning, in carboxypeptidase enzymes;(24, 25) and endocrine functioning, in the 
synthesis of insulin (46-48) thanks to the presence of zinc transporter in the tissue.(49, 50) 
These studies indicated that the presently produced 63Zn met the laboratory necessity for 
molecular imaging with PET. Recent efforts are being made to estimate beta-cell mass by non-
invasive in vivo imaging for better understanding the diabetes pathogenesis and monitoring 
therapeutic recovery of the cell.(51) The findings in this study along with previous ones using 
62/65Zn (24-27, 43, 52, 53) imply that 63Zn would be useful for estimating pancreatic functions 
by PET imaging. Additionally, zinc and its transporters are involved in a variety of biological 
processes in the body and alterations are related to chronic pathologies such as, Alzheimer’s 
disease (7, 22) that could be investigated using 63Zn. 
 
Figure 1.6. Representative chest/abdominal PET images of [63Zn]Zn (16 MBq) in the 
isoflurane-anesthetized rat. PET images were generated by summation of the whole scan (0–60 
min). %ID/ml (Percentage of injected dose per ml) 
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1.4. Conclusions 
The production and purification of the PET radionuclide 63Zn was established. The 
procedure was rapid and straightforward, and the product was obtained in high chemical and 
radiochemical purities. The typical accumulation of zinc in liver and kidneys, as well as in the 
pancreas, was observed in the PET image study. Therefore, the presently produced 63Zn has 
become available for molecular imaging with PET. 
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Chapter 2.                                                                                            
Synthesis and Evaluation of Diastereoisomers of          
1,4,7-triazacyclononane-1,4,7-tris-(glutaric acid) (NOTGA) 
for Multimeric Radiopharmaceuticals of Gallium 
2.1. Introduction 
Gallium radioisotopes are of great interest for molecular imaging. Gallium-68 (68Ga) is a 
PET radioisotope available from long-lived 68Ge/68Ga generator systems allowing potentially 
cost-effective production of 68Ga radiotracers far away from a cyclotron facility. Its physical 
half-life of 67.7 min is attractive for labeling low molecular weight probes with rapid 
pharmacokinetics.(54) 
For preparing 68Ga-based radiotracers, a macrocyclic chelator 1,4,7-triazacyclononane-
N,N’,N”- triacetic acid (NOTA, Figure 2.1 A) is preferably used due to the formation of a 
hexadentate gallium complex of high thermodynamic (Log K = 30.98) (55) and kinetic 
stabilities arising from the good fit of the relatively small gallium cation in the cyclic cavity.(54) 
Moreover, this chelator has been efficiently radiolabeled with 68Ga, even at room 
temperature.(13, 56, 57) 
Since the conjugation of targeting molecules to the carboxylic acids of NOTA compromises 
its coordination ability with Ga, several NOTA-based bifunctional chelating agents (BCA) with 
dissimilar functional groups in a pendant arm or on an ethylene bridge have been 
developed.(12-15) Triazacyclononane (TACN) has been selected as the core of the scaffold 
containing phosphinic acid (triazacyclononane phosphinic acids; TRAP) (58, 59) or glutaric 
acid (nonane triglutaric acid; NOTGA) (16, 17) for multi-attachment of biomolecules to the 
three pendant arms as a way to apply to the multivalent concept (Figure 2.1 B and C). 
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Figure 2.1. Structures of (A) NOTA and the NOTA-based BCAs, (B) TRAP and (C) NOTGA. 
TRAP contains phosphinic acids whereas NOTGA glutaric acids 
Recently, Singh et al.(17) exemplarily demonstrated that the binding affinity and tumor 
accumulation of a trivalent cyclic RGD peptide conjugated-NOTGA (68Ga-3) increased with 
respect to its bivalent and monovalent counterparts. Similarly, Notni et al. reported that the 
targeting ability of the trivalent 68Ga-TRAP(RGD)3 was superior to that of the monovalent 18F-
Galacto-RGD.(59) However, one aspect to consider when preparing NOTGA- and TRAP-based 
radiopharmaceuticals is the presence of chiral centers in their pendant arms leading to RRR, SSS, 
RRS, SSR stereoisomers. In NOTGA, these stereoisomers are formed as a result of the alkylation 
of TACN with racemic (R/S) -bromoglutaric acid diester (Figure 2.2), which was also 
observed in the alkylation of tetraazacyclododecane,(60, 61) where the RRRR isomer of 
gadolinium complex exhibited faster water exchange rate than the other isomers.(61) 
In TRAP ligands, the phosphorous atoms become chiral upon coordination with the metal 
ion and four RRR, SSS, SSR, RRS isomers are formed depending on the substituent.(58, 62) A 
mixture of diastereomers, with differences in spatial orientation of the chelating unit or targeting 
molecules and physicochemical properties, might influence the biodistribution of the molecular 
probe.(63, 64) In cases where radiopharmaceuticals can form distinct isomeric species, it is 
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important to evaluate the individual product separately to ensure that they both possess good 
biological efficacy,(63) as well as stability and radiochemistry. 
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Figure 2.2. Structures of the isomeric forms of NOTGA. The RRR and SSS, as well as RRS and 
SSR constitute enantiomers; while the pairs RRR/SSS and RRS/SSR are diastereomers 
In TRAP-based radiolabeled probes, separation of a potential diastereomer can only be 
conducted after radiolabeling reaction. On the other hand, the isolation of diastereomers in 
NOTGA is feasible after alkylation of TACN, and diastereomerically pure conjugates can be 
obtained. In NOTGA-based radiolabeled probes, therefore, a diastereomerically pure 68Ga-
labeled compound can be obtained without post-labeling purification by selecting a 
diastereomer of preferable chemical and biological performance. In the present study, pure 
diastereomers of NOTGA using RGDfK as the targeting molecule, were synthesized, and 
compared their performance in terms of radiochemical yields using the more convenient 67Ga 
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(T1/2 = 3.3 d), kinetic stability, affinity for integrin v3, and biological behavior of each 
complex in normal and nude mice bearing U87MG tumor xenografts.  
2.2. Materials and Methods 
2.2.1. General 
All commercially obtained chemicals were of analytical grade and used without further 
purification. 9-Fluorophenylmethoxycarbonyl (Fmoc)-protected amino acids and H-Gly-2-Cl-
Trt Resin were purchased from Watanabe Chemical Industries, Ltd. (Hiroshima, Japan). 67GaCl3 
was supplied by FUJIFILM RI Pharma Co., Ltd. (Tokyo, Japan). 1,4,7-Triazacyclononane 
(TACN) was purchased from Sigma Aldrich Chem. Co. (Milw, WI, USA). Apo-Transferrin 
(apo-Tf) Iron free was purchased from Nacalai Tesque Inc. (Kyoto, Japan). Reversed phase 
(RP) HPLC  was performed with a Cosmosil 5C18-AR-300 column (4.6 mm I.D. × 150 mm, 
Nacalai Tesque Inc.) at 1 mL/min with a gradient mobile phase starting from 90% A (0.1% 
aqueous trifluoroacetic acid (TFA) and 10% B (acetonitrile with 0.1% TFA) to 70% A and 30% 
B at 30 min. The eluent was monitored online with a UV-Vis single beam spectroscopy detector 
(L-7405, Hitachi Co. Ltd., Tokyo) coupled to a NaI(Tl) radioactivity detector (Gibi star, Raytest, 
Strubenhardt, Germany). TLC analyses was performed with silica plates (Silica gel 60 F254, 
Merck Ltd., Tokyo) developed with MeOH/0.1 M AcONH4 (1:1). Radioactivity was measured 
using a MiniGita Star Gamma TLC Scanner (Raytest) and an auto well γ counter (ARC-380M, 
Aloka, Tokyo). Mass spectrometry was carried out using an Agilent 6130 Series Quadrupole 
LC/MS electrospray system (Agilent Technologies, Tokyo) or MALDI TOF MS Kratos Axima 
CFR Plus (Shimadzu Corporation, Kyoto). 1H, 13C-NMR spectra were recorded on a JEOL 
JNM-ECP-400 (400 MHz) spectrometer (JEOL Ltd., Tokyo). 
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Scheme 2.1. Synthesis of NOTGA-(TEG-RGD)3: (a) Fmoc-O-Su, K2CO3, H2O; (b) c(-
Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys-), EDC, HOBt, DMF; (c) 10% piperidine/DMF; (d) 1,4,7-
triazacyclononane, K2CO3, MeCN; (e) 10% Pd/C, MeOH, H2O; (f) H2N-TEG-
c(R(Pbf)GD(OtBu)fK), EDC, DIMAP, CH2Cl2; (g) TFA/ H2O /Et3Si 
2.2.2. Synthetic procedures 
 (2-{2-[2-(9H-Fluoren-9-ylmethoxycarbonylamino)-ethoxy]-ethoxy}-ethoxy)-acetic acid (1) 
(Fmoc-TEG). 11-Amino-3,6,9-trioxaundecanoic acid (0.79 g, 3.79 mmol) and K2CO3 (1.04 g, 
7.50 mmol) were dissolved in 5.8 mL of water and stirred at room temperature for 15 minutes 
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after which N-(9-fluorenylmethoxycarbonyl) succinimide (1.28 g, 3.79 mmol) was added and 
the mixture was stirred for 24 h, while the progress of the reaction was monitored by TLC 
(CHCl3/MeOH/AcOH, 5/1/0.06). The salt was filtrated and the filtrate was washed with 3 × 3 
mL of Et2O, acidified to pH 1 using 3 N HCl and the desired compound extracted with 5 × 5 mL 
of CH2Cl2. After removing the solvent in vacuo, the residue was purified with open column 
chromatography using silica gel and subsequent elution with CHCl3/MeOH/AcOH (40:1:0.1) to 
afford Fmoc-TEG (1.19 g, 73%). ESI-MS, m/z: 430 [M+H]+: Found 430. 
Synthesis of Fmoc-TEG-c(-Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys-) (2). Fmoc-TEG (0.16 
g, 0.36 mmol), c(-Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys-) (0.3 g, 0.33 mmol) (65) and 1-
hydroxybenzotriazole monohydrate (HOBt, 0.049 g, 0.36 mmol) were dissolved in 13 mL of 
dimethylformamide (DMF) and cooled to -3 °C. Subsequently, 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimidehydrochloride (EDC, 0.21 g, 1.08 mmol) in 12 mL of DMF 
was added dropwise during 1 h under N2 atmosphere. The reaction mixture was further stirred 
for 1 h and then reacted overnight at room temperature. The solvent was removed in vacuo and 
then the residue dissolved in 100 mL of CH2Cl2 was washed with 5% citric acid (2 × 40 mL). 
The organic layer was collected and dried over MgSO4. After removing the solvent in vacuo, 
the residue was purified with open column chromatography using silica gel and subsequent 
elution with CHCl3/MeOH (20:1) to obtained compound 2 as a white solid (0.22 g, 51%). ESI-
MS, m/z: 1345 [M+Na]+: Found 1345. 
Synthesis of TEG-c(-Arg(Pbf)-Gly-Asp(OtBu)-DPhe-Lys-) (3). Fmoc-TEG-c(-Arg(Pbf)-
Gly-Asp(OtBu)-D-Phe-Lys-) (0.47 g, 0.35 mmol) was dissolved in 23 mL of 10% piperidine 
DMF solution and then stirred for 2 h. After concentrating the solvent, Et2O was added to the 
solution. The white precipitate was filtrated, washed alternatively with Et2O and n-hexane, dried 
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in vacuum overnight to obtain compound 3 as a yellow solid (0.30 g, 76%). ESI-MS, m/z: 1101 
[M+H]+: Found 1101. 
1,4,7-Tris-(1-tert-butoxycarbonyl-3-benzyloxycarbony-propyl)-1,4,7-
triazacyclononane (4) (NOTGA-tBu3-Bz3). (R/S) -Bromoglutaric acid 1-tert-butyl ester 5-
benzyl ester (1.3 g, 3.64 mmol) (66) was dissolved in 3.5 mL of acetonitrile and the solution 
was added dropwise to a solution of 1,4,7-triazacyclononane (0.142 g, 1.10 mmol) in 3.3 mL 
acetonitrile with K2CO3 (0.913 g, 6.62 mmol) during 2 h at 0C under N2. The mixture was 
stirred at room temperature for 24 h. The reaction mixture was filtrated and the solvent was 
evaporated in vacuo. The residue was dissolved in dichloromethane (15 mL) and washed with 
5% NaHCO3 (3 × 10 mL) and the organic layer was dried over MgSO4. After removing the 
solvent in vacuo, the residue was purified with open column chromatography using silica gel 
and subsequent elution with chloroform/acetone (50:1) to afford compound 4 as yellowish oil. 
RRR/SSS (0.637 g, 69%): 1H-NMR (400 MHz, CDCl3),  (ppm): 7.28–7.34 (m, 15H, Ph); 5.10 
(s, 6H, CH2–Ph); 3.09–3.13 (t, 3H, N–CH); 2.68, 2.95 (d, J = 0.03, 12H, N-CH2-CH2-N); 2.42–
2.53 (m, 6H, CH2–COOBz); 1.82–2.03 (m-m, 6H, N-CH-CH2); 1.43 (s, 27H, C(CH3)3). 13C-
NMR (100 MHz, CDCl3),  (ppm): 173.06 (COOBzl); 173.27 (COO-tBu); 128.13, 128.17, 
128.49, 136.02 (Ph); 81.80 (C-Me3); 67.26 (C-Ph); 66.14 (N-C); 54.24 (N-C-C-N); 31.27 (C-
COO-Bzl); 28.26 (tBu); 25.26 (C-COO-Bzl). RRS/SSR (0.165 g, 17%): 1H-NMR (400 MHz, 
CDCl3),  (ppm): 7.27–7.34 (m, 15H, Ph); 5.10,5.09 (s-s, 6 H, CH2–Ph); 3.09–3.14 (m, 3H, N–
CH); 2.93 (d, J = 0.03, 2H, N-CH2); 2.70–2.84 (m, 8H, N-CH2-CH2-N); 2.58 (d, J = 0.03, 2H, 
CH2-N); 2.40–2.55 (m, 6H, CH2-COOBz); 1.80–2.04 (m-m, 6H, N-CH-CH2); 1.43,1.44 (s-s, 
27H, C(CH3)3). 13C-NMR (100MHz, CDCl3),  (ppm): 173.34, 173.45 (d, COOBzl); 172.62, 
172.74 (d, COO-tBu); 128.41, 128.46, 128.77, 136.31 (Ph); 81.09, 81.11 (C-Me3); 67.25 (C-Ph); 
 - 35 - 
 
66.40, 66.59 (N-C); 53.85, 54.16, 54.60 (N-C-C-N); 31.33, 31.51 (C-COO-Bzl); 28.56 (tBu); 
25.48, 25.65 (C-COO-Bzl). ESI-MS, m/z: 958 [M+H]+, Found 958. 
1,4,7-(-Bromoglutaric acid 1-tert-butyl ester 5-benzyl ester)-1,4,7 triazacyclononane 
(5) (NOTGA-tBu3). The RRR/SSS (0.57 g, 0.59 mmol) or RRS/SSR (0.15 g, 0.16 mmol) 
fractions were dissolved in methanol/water (5:1) and then 10% Pd/C (381 and 103 mg, 
respectively) was added portionwise. The mixtures were stirred for 12 h under H2 atmosphere. 
Then filtered over Celite, and evaporated to dryness to obtain compound 5 as white solids. The 
products were used without further purification. RRR/SSS (408 mg, 96.4%). 1H-NMR (400 MHz, 
CD3OD), (ppm): 3.69–3.70 (br, 3H, N-CH); 2.99–3.13 (br, 12H, N-CH2-CH2-N); 2.52–2.64 
(br, 6H, CH2-COOH); 2.06–2.19 (br, 6H, N-CH-CH2); 1.51 (s, 27H, C(CH3)3). RRS/SSR (104 
mg, 95%). 1H-NMR (400 MHz, CD3OD), (ppm): 3.62–3.72 (br, 3H, N-CH); 2.87–3.22 (br, 
12H, N-CH2-CH2-N); 2.44–2.81 (br, 6H, CH2-COOH); 2.19–2.15 (br, 6H, N-CH-CH2); 1.51 (s, 
27H, C(CH3)3). ESI-MS, m/z: 688 [M+H]+, Found 688. 
NOTGA-(TEG-RGD)3 (6). NOTGA-tBu3 (RRR/SSS, 8.52 mg, 12.4 μmol; RRS/SSR, 10 mg, 
14.5 μmol) was dissolved in dry CH2Cl2 (0.5 mL) and 0.3 eq of 4-dimethylaminopyridine 
(DMAP), 3.5 eq of TEG-c(-Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys-), 3.6 eq of EDC dissolved in 
0.5 mL of CH2Cl2 were added dropwise on an ice bath. After stirring at room temperature for 12 
h under N2, the solvent was evaporated in vacuo. The residue was dissolved in CH2Cl2 (10 mL), 
washed with 5% NaHCO3 (3 × 7 mL) and dried over MgSO4. After removing the solvent, the 
residue was taken up by a small amount of CHCl3. The precipitate formed upon addition of 
excess of Et2O was filtrated and dried in vacuum overnight to obtain the protected conjugate 
intermediate as a yellow solid (RRR/SSS, 33.3 mg, 68.2%; RRS/SSR, 38.7 mg, 67.6%). ESI-MS, 
m/z: 1683.9 [M+2H]2+: Found 1685.5. After treatment with TFA/triethylsilane/H2O (90:5:5) at 
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room temperature for 3 h, the solvent was evaporated in vacuo and the precipitate formed upon 
addition of excess of Et2O (RRR/SSS, 17.8 mg, 64.6%; RRS/SSR, 16 mg, 57.1%). ESI-MS, m/z: 
1422 [M+2H]2+: Found 1422. 
Ga-NOTGA-(TEG-RGD)3. NOTGA-(TEG-RGD)3 (RRR/SSS, 0.8 mg, 0.28 μmol; 
RRS/SSR, 3 mg, 1.05 μmol) was dissolved in 500 L of water, and 0.1 M Ga(NO3)3 solution 
(4.4 and 14.3 L, respectively) were added. After 10 min heating at 70°C, the pH was adjusted 
from 1.9 to 3.5 using 1 M sodium acetate and heated for another 30 min. The complex was 
purified by preparative HPLC and lyophilized to obtain Ga-NOTGA-(TEG-RGD)3 (RRR/SSS, 
0.7 mg, 85%; RRS/SSR, 2.67 mg, 87%). ESI-MS, m/z: 1455 [M+2H]2+, Found 1455.  
2.2.3. 67Ga-Radiolabeling 
The complexation of 67Ga by both diasteremeric pair of ligands was studied regarding the 
reaction pH and time at room temperature. 67GaCl3 (10 L, 1.5 MBq) in 0.05 M HCl was mixed 
with 10 L of 0.5 M sodium acetate buffer (A.B.) pH 4 – 5.5. The mixtures were added to 
Eppendorf tubes containing 0.4 nmol of ligand in 20 L of 0.25 M acetate buffer pH 3 – 5.5 to 
give final solutions of 0.25 M A.B., pH 3.5 – 5.5 and 10 M of ligand concentration. The 
mixtures were incubated at 25ºC for 5, 10 and 15 min and radiochemical yield were determined 
by Radio-TLC. 
2.2.4. In vitro stability 
67Ga labeled complexes (RRR/SSS, RRS/SSR) were purified by RP-HPLC to remove 
unlabeled ligands. The radioactive peak was collected and the solvent was removed in vacuo. 
The residue was reconstituted in apo-Tf solution (50 M, 0.1 M carbonate buffer, pH 7.4) and 
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incubated at 37C. Samples were withdrawn at 1, 3 and 6 h and analyzed by Radio-TLC (n = 3). 
2.2.5. Binding affinity to integrin v3 
 To evaluate the binding affinity of Ga labeled compounds to integrin v3, surface plasmon 
resonance (SPR) technology-based ProteOn™ XPR36 protein interaction array system (Biorad 
Laboratories Japan, Yokohama, Japan) was used. The SPR experiment was performed 
according to the manufacturer’s instruction. In brief, human purified integrin v3 (20 g/mL, 
Chemicon International, Temecula, CA, USA) dissolved in 10 mM A.B. (pH 4.0) was 
immobilized on a ProteOn GLH sensor chip (Biorad Laboratories Japan) by standard amine 
coupling method. The Ga-NOTGA-(TEG-RGD)3 complexes (RRR/SSS, RRS/SSR) at 10, 5, 2.5 
and 1.25 M concentrations and c(RGDfk) at 200, 100, 50, 25 and 12.5 M as a positive control 
in 10 mM Tris-HCl buffer (50 mM NaCl, 1 mM MgCl2, 1 mM MnCl2, pH 7.4) were injected 
simultaneously into the six horizontal channels of the chip. Kinetic analysis was performed by 
globally fitting curves describing a simple 1:1 biomolecular model to the set of five 
sensorgrams. 
2.2.6. Cell line 
Human glioblastoma U87MG cells were grown in a 75 cm2 tissue culture flask with canted 
neck (Becton, Dickinson and Company, Tokyo) in Dulbecco’s Modified Eagle Medium (Sigma-
Aldrich Japan K.K., Tokyo) supplemented with 10% fetal calf serum (FCS, Nippon Bio-supply 
Center, Tokyo) and GIBCO BRL 1% penicillin–streptomycin (5000 unit – 5000 g/mL, 
Invitrogen, Life Technologies Japan Ltd., Tokyo), at 37°C in a humidified atmosphere 
containing 5% CO2.  
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2.2.7. Biodistribution studies 
Animal studies were conducted in accordance with institutional guidelines approved by the 
Chiba University Animal Care Committee. Male ddY mice (67) (Japan SLC, Inc., Shizuoka, 
Japan) of 6-week-old were injected via tail vein with either RRR/SSS or RRS/SSR diastereomers 
of 67Ga-NOTGA-(TEG-RGD)3 (100 L, 11.1 KBq, 10 M ligand concentration). The animals 
were sacrificed and dissected at 30 min, 1 h, 3 h and 6 h after administration. Tissues of interest 
were removed, weighted and the radioactivity counts were determined with an auto well gamma 
counter. The urine and feces were collected for 6 h and the radioactivity was also measured. 
Values were expressed as mean ± SD for a group of 3 – 5 animals. 
BALBc nu/nu male mice (Japan SLC, Inc, Shizuoka, Japan) of 6-week-old, 18 – 20 g, were 
xenografted by subcutaneous (s.c.) injection of U87MG human glioblastoma cells (5 × 106 
cells/80 L of culture medium) into their right hind legs. The mice were subjected to 
biodistribution studies as well as SPECT/CT imaging studies when the tumor volume reached 
100 – 300 mm3.  
Biodistribution studies were also conducted in male BALBc nu/nu mice bearing U87MG 
xenografts 30 min after administration of each radiotracer (n = 4). The integrin v3 specificity 
was estimated by co-injection of either RRR/SSS or RRS/SSR diastereomers of 67Ga-NOTGA-
(TEG-RGD)3 (100 L, 11.1 KBq, 10 M ligand concentration) and c(RGDyV) peptide (3 
mg/kg mouse body weight) into mice bearing U87MG tumors. The animals were sacrificed and 
dissected at 2 h after administration (n = 4). 
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2.2.8. Small Animal SPECT/CT imaging studies 
SPECT/CT images were taken 30 min after administration of either RRR/SSS or RRS/SSR 
diastereomers of [67Ga]-NOTGA-(TEG-RGD)3 (100 L, 4.5 MBq, 10 M ligand concentration) 
to male BALBc nu/nu mice bearing U87MG xenografts from the tail vein (n = 3). The mice 
were anaesthetized with 1 – 2% (v/v) isoflurane (DS Pharma Animal Health, Osaka, Japan) and 
positioned on the animal bed where anesthesia was continuously delivered via a nose cone 
system. SPECT imaging and X-ray CT imaging were performed by use of small animal 
SPECT/CT system (FX-3200, Gamma Medica Inc., CA) equipped with five pinholes (0.5 mm) 
collimator. Data acquisition was performed for 64 min at 60 s per projection with stepwise 
rotation of 64 projections over 360˚. 
2.2.9. Statistical analysis 
Quantitative data were expressed as mean ± SD. Means were compared using unpaired two-
tailed Student’s t test. P values <0.05 were considered statistically significant. 
2.3. Results 
2.3.1. Chemical synthesis 
TACN was alkylated with (R/S) -bromoglutaric acid 1-tert-butyl ester 5-benzyl ester (15, 
66, 68) in acetonitrile and K2CO3 at room temperature to obtain the fully protected NOTGA-
tBu3-Bz3 4 (Scheme 2.1). Purification was carried out using silica-gel column chromatography 
and a mixture of chloroform and acetone as the mobile phase. Two fractions (a major fraction of 
69% and the following of 17%) were verified to be the target compound by mass spectrometry. 
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Structure assignment was possible by 1H-NMR and 13C-NMR, which provides deeper insights 
into their structural differences (Figure 2.3 – 2.5). Focusing on the chiral carbon (label b in 
Figure 2.3), a single resonance was observed in the 69% fraction Figure 2.3 A) indicating 
equivalent carbons, and two resonances in the 17% fraction indicating the presence of two 
chemically non-equivalent carbons (Figure 2.3 B). The 69% fraction was assigned to the 
RRR/SSS diastereomeric pair and the 17% to the RRS/SSR.  
In order to evaluate the differences of both diastereomeric pairs, each fraction was treated 
separately. After debenzylation by palladium catalyzed hydrogenolysis, the diastereomeric 
orthogonally protected NOTGA-tBu3 prochelators were obtained in quantitative yields. 
The peptide substituent was prepared using an Fmoc chemistry to introduce the TEG spacer 
in the lysine side chain of c(RGDfK) in 50 % yield. The prochelators of NOTGA-tBu3 were then 
conjugated to the partially protected TEG-c(-Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys-) by in situ 
activation using the standard EDC based coupling method followed by complete removal of all 
protecting groups to obtain the desired ligands at moderate yields after HPLC purification (> 
95% purity). 
 - 41 - 
 
 
Figure 2.3. 13C NMR (100MHz, CDCl3, 25 C) spectra of NOTGA-tBu3-Bz3 products 
obtained from alkylation of TACN with (R/S)--bromoglutaric acid 1-tert-butyl ester 5-
benzyl ester, followed by column chromatography. (A) The major fraction (69 %) 
corresponds to RRR/SSS enantiomers while (B) the minor fraction (17 %) to RRS/SSR 
diastereomers. See inserted structural formula for assignments 
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Figure 2.4. 1H NMR (400 MHz, CDCl3, 25 C) spectra of NOTGA-tBu3-Bz3 from the 
alkylation of TACN with (R/S)--bromoglutaric acid 1-tert-butyl ester 5-benzyl ester. Column 
chromatography isolated fraction (69%) corresponding to RRR/SSS enantiomers. See inserted 
structural formulas for assignments 
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Figure 2.5. 1H NMR (400MHz, CDCl3, 25 C) spectra of NOTGA-tBu3-Bz3 from the alkylation of 
TACN with (R/S)--bromoglutaric acid 1-tert-butyl ester 5-benzyl ester. Column chromatography 
isolated fraction (17%) corresponding to the RRS/SSR diastereomers. See inserted structural 
formulas for assignments 
2.3.2. Radiochemistry 
The RRR/SSS and RRS/SSR pairs of NOTGA-(TEG-RGD)3 were radiolabeled with 67Ga and 
the resulting complexes were analyzed by HPLC (Figure 2.6). In both cases, a single peak was 
observed and the retention time of the RRR/SSS was 24.5 min, slightly longer than that of 
RRS/SSR (24.3 min). In both cases, their retention times were identical to those of the 
corresponding non-radioactive gallium complexes verified by mass spectrometry. 
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Figure 2.6. HPLC radiochromatograms of 67Ga-NOTGA-(TEG-RGD)3. The RRR/SSS 
diastereomer (top) was eluted at 24.5 min slightly longer than that of the RRS/SSR counterpart 
(bottom, 24.3 min) 
Formation kinetic as a function of pH is presented in Figure 2.7. In both cases, 
radiochemical yields were low under acidic conditions (pH 3.5) and quantitative at higher pH. 
Interestingly, while RRR/SSS was preferentially labeled at pH 5 the RRS/SSR was pH 
independent from pH 4 to 5.5 (Figure 2.7 A). Nevertheless, at pH 5 the time variation of the 
radiochemical yield was essentially the same for both pairs (Figure 2.7 B) and complete 
radiolabeling with more than 98% yield was attained after 10 min of reaction. Under the present 
conditions, the specific activity of the 67Ga-labeled compounds was 4,500 MBq/µmol. 
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Figure 2.7. Radiochemical yields of each diastereomer of 67Ga-NOTGA-(TEG-RGD)3 
(RRR/SSS: squares, and RRS/SSR: triangles) (A) at different pH values for 10 min and (B) 
different reaction times at pH 5.0 
2.3.3. In vitro stability 
The kinetic stability of [67Ga]-NOTGA-(TEG-RGD)3 diastereomeric pairs, purified by 
HPLC in order to remove the excess of ligand, was estimated in an apo-Tf challenge (Table 2.1). 
After 6 h of incubation at 37°C, more than 98% of the radioactivity was still bound to the 
NOTGA tri-peptide conjugates of both pairs. 
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Table 2.1. Stability of 67Ga-NOTGA-(TEG-RGD)3 diastereomers against apo-Tfa 
Time (h) Percent of intact radiolabeled complex 
 RRR/SSS RRS/SSR 
1 98.6 ± 0.2  98.9 ± 0.4 
3 98.9 ± 0.3  98.3 ± 0.9 
6 98.0 ± 0.4  98.4 ± 0.2 
aResults are expressed as mean ± SD of three experiments 
2.3.4. Binding affinity 
The binding kinetics of the two diasteromeric gallium complexes of NOTGA-(TEG-RGD)3 
to v3 integrin was estimated with the SPR technology using a monovalent c(RGDfK) as a 
reference (Table 2.2). Both diastereomeric trivalent complexes exhibited higher association and 
lower dissociation rates than that of a monovalent c(RGDfK) with the rate constants similar 
each other. As a result, both trivalent complexes showed 10-folder lower dissociation constant 
values (KD) than that of monovalent c(RGDfK). 
Table 2.2. Kinetic binding constants of 67Ga-NOTGA-(TEG-RGD)3 (RRR/SSS and RRS/SSR), 
c(RGDfK) to integrin v3 determined using the SPR technology 
Analyte Ka (1/Ms) Kd (1/s) KD(M) 
RRR/SSS 1.13 × 105 ± 6.8 × 103 8.03 × 10-3 ± 1.7 × 10-4 7.13 × 10-8 ± 4.5 × 10-9 
RRS/SSR 0.94 × 105 ± 5.3 × 103 8.12 × 10-3 ± 1.6 × 10-4 8.64 × 10-8 ± 4.9 × 10-9 
c(RGDfK) 2.57 × 104 ± 6.1 × 103 1.38 × 10-2 ± 6.2 × 10-4 5.37 × 10-7 ± 2.7 × 10-7 
2.3.5. In vivo experiments 
The results of the biodistribution studies of [67Ga]-NOTGA-(TEG-RGD)3 in normal mice at 
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30 min, 1 h, 3 h and 6 h after administration are shown in Table 2.3 (RRR/SSS) and Table 2.4 
(RRS/SSR). No significant differences were observed in the uptake of both diastereomers in 
almost all organs and tissues. These profiles were characterized by rapid blood clearance with 
low accumulation in the liver and the majority of the radioactivity was localized in the kidneys.  
Table 2.3. Biodistribution of RRR/SSS diastereomer of 67Ga-NOTGA-(TEG-RGD)3 in normal 
micea 
RRR/SSS 
Organ 30 min 1 h 3 h 6 h 
Blood 0.61 ± 0.13 0.16 ± 0.02 0.07 ± 0.02 0.09 ± 0.02 
Liver 1.27 ± 0.22 1.32 ± 0.15 1.49 ± 0.32 1.50 ± 0.30 
Spleen 2.09 ± 0.35 1.26 ± 0.12 1.32 ± 0.21 1.77 ± 0.56 
Kidneys 5.82 ± 1.22 5.04 ± 1.15 3.48 ± 0.54 3.00 ± 0.43 
Pancreas 1.06 ± 0.19 0.72 ± 0.09 0.65 ± 0.10 0.66 ± 0.13 
Heartb 1.00 ± 0.07 0.69 ± 0.05 0.65 ± 0.09 0.73 ± 0.11* 
Lung 2.52 ± 0.33 1.41 ± 0.11 1.08 ± 0.37 1.25 ± 0.47 
Muscle 0.84 ± 0.14 0.55 ± 0.12 0.51 ± 0.07 0.52 ± 0.04 
Stomachc 0.63 ± 0.06 0.74 ± 0.16 0.56 ± 0.13 0.47 ± 0.14 
Intestinesb,c  2.98 ± 0.54 3.67 ± 0.27** 5.23 ± 0.80* 4.44 ± 0.26** 
Urinec    63.22 ± 6.83 
Fecesc    4.25 ± 1.30 
aData expressed as %ID/g  SD (n = 5). b* p < 0.05, ** p < 0.01 in comparison to RRS/SSR. cExpressed 
as %ID 
Both radioligands were excreted in the urine with a small amount in feces. Although in 
absolute terms the uptake in the intestines was very low, a slight tendency of the RRR/SSS to be 
excreted through the intestinal tract can be noted. Its intestine accumulation was significantly 
higher at 1, 3 and 6 h p.i. Likewise, relatively higher radioactivity in feces and lower 
radioactivity in urine for the RRR/SSS were observed.  
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Table 2.4. Biodistribution of RRS/SSR diastereomer of 67Ga-NOTGA-(TEG-RGD)3 in normal 
micea 
RRS/SSR 
Organ 30 min 1 h 3 h 6 h 
Blood 0.58 ± 0.18 0.19 ± 0.02 0.09 ± 0.03 0.08 ± 0.02 
Liver 1.22 ± 0.12 1.19 ± 0.07 1.56 ± 0.38 1.33 ± 0.19 
Spleen 1.42 ± 0.59 1.20 ± 0.17 1.40 ± 0.06 1.57 ± 1.17 
Kidneys 5.38 ± 0.89 4.74 ± 0.87 3.58 ± 0.39 3.04 ± 0.28 
Pancreas 0.85 ± 0.07 0.69 ± 0.03 0.71 ± 0.09 0.58 ± 0.11 
Heartb 0.93 ± 0.16 0.73 ± 0.08 0.73 ± 0.09 0.55 ± 0.05* 
Lung 1.94 ± 0.53 1.36 ± 0.16 1.33 ± 0.35 1.00 ± 0.04 
Muscle 1.22 ± 0.91 0.55 ± 0.04 0.55 ± 0.06 0.62 ± 0.17 
Stomachb 0.59 ± 0.06 0.63 ± 0.11 0.61 ± 0.11 0.40 ± 0.02 
Intestinesb  2.59 ± 0.35 3.00 ± 0.27** 4.10 ± 0.62* 2.90 ± 0.38** 
Urineb    71.52 ± 2.64 
Fecesb    2.24 ± 0.89 
aData expressed as %ID/g  SD (n = 5). bExpressed as %ID 
Figure 2.8 shows the biodistribution studies of [67Ga]-NOTGA-(TEG-RGD)3 (RRR/SSS and 
RRS/SSS) at 30 min postinjection to nude mice bearing U87MG xenografts. The biodistribution 
profiles of both diastereomeric pairs were characterized by rapid blood clearance, high tumor 
uptake with comparatively low accumulation in non-target organs and renal excretion pathway. 
In agreement with the studies in normal mice, the uptakes of the diastereomeric pairs in organs 
of interest were comparable. Tumor uptakes were 4.40  0.38 and 4.77  0.76 %ID/g (p<0.05) 
for RRR/SSS and RRS/SSR, respectively. Tumor to organ ratios (Figure 2.8 B) were high for 
blood and muscle, moderate for the liver and much lower for the kidney. A combination of 
slightly higher tumor and lower blood uptakes led to a statistically significantly higher tumor to 
blood ratio for the RRS/SSR pair. 
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Figure 2.8. (A) Biodistribution of 67Ga-NOTGA-(TEG-RGD)3 in tumor-bearing male nude 
mice at 30 min after intravenous injection of 11.1 KBq of RRR/SSS (white) or RRS/SSR (black). 
(B) The tumor to organ ratios of the 67Ga labeled conjugates. Data expressed as %ID/g  SD    
(n = 4, ** p < 0.01) 
When the radiolabeled probes were co-injected with a high amount of RGDyV, tumor 
accumulation was significantly decreased (p < 0.05) to 0.82  0.17 and 0.68  0.2 %ID/g at 2 h 
p.i. (RRR/SSS and RRS/SSR, respectively), demonstrating integrin v3 targeting specificity 
(Figure 2.9). 
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Figure 2.9. Biodistribution data in tumor-bearing male nude mice at 2 h after administration of 
67Ga-NOTGA-(TEG-RGD)3 with (black) and without (white) the presence of an excess of 
RGDyV. (A) RRR/SSS; (B) RRS/SSR. Data expressed as %ID/g  SD (n = 4) 
SPECT/CT imaging studies were performed for both RRR/SSS and RRS/SSS diastereomers 
of [67Ga]-NOTGA-(TEG-RGD)3 using nude mice bearing U87MG xenografts (Figure 2.10). 
Tumors were clearly visualized as early as 30 min after administration. Radioactivity was 
concentrated in the kidneys and bladder. Impressively, non-specific accumulation in liver or 
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bowel was not observed resulting in high contrast images. 
 
Figure 2.10. SPECT/CT images of U87MG tumor-bearing male nude mice after 30 min of i.v. 
injection of 4.5 MBq of each diastereomer of [67Ga]-NOTGA-(TEG-RGD)3. (A) RRR/SSS and 
(B) RRS/SSR. Images were shown at the same signal intensity scale 
2.4. Discussion 
The cyclic RGD peptides have been widely study as a targeting molecule due to its high 
affinity for integrin v3 over-expressed during tumor angiogenesis.(11) It has also been well 
recognized that in vitro binding affinity and in vivo tumor targeting ability of multimeric RGD 
peptides are enhanced due to the multivalent effect and the enriched local RGD 
concentration.(11, 18-21) Moreover, it has been demonstrated that the spacer units of 
appropriate length and hydrophilicity between a radiometal chelate and each RGD motif 
increase avidity of the radiotracers and simultaneously may act as pharmacokinetic modifier to 
improve pharmacokinetics of the radiotracer.(11, 69, 70)  
The preparation of NOTA-based radiopharmaceuticals was conducted according to the 
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procedure reported previously.(16, 17) In brief, the synthesis of the orthogonally protected 
prochelator NOTGA-tBu3 took place first, followed by conjugation of the bioactive molecules to 
each carboxylic acid of the pendant arm and final deprotection. Intermediate 4 exists in different 
isomeric forms,(60, 61) RRR, SSS, RRS, and SSR (Figure 2.2) due to the use of the (R/S) 
racemates of -bromoglutaric acid 1-tert-butyl ester 5-benzyl in the alkylation of TACN. They 
were synthesized from (S)-glutamic acid-5-benzyl ester through bromination by diazotization 
with sodium nitrite in NaBr/HBr solution as previously.(15, 17, 60, 66) This reaction is not 
stereoselective and the -bromo acid product is only enantioenriched as reported.(71) Further 
methods should be devised at this stage to isolate the major fraction by chiral chromatography 
or by using enantioselective bromination reactions.(72) The RRR and SSS isomers constitute 
enantiomers with three equivalent chiral carbons and the pair was assigned to the 69% fraction 
with a single resonance at the corresponding position in 13C-NMR. Enantioenriched reactants 
may have favored the formation of this two enantiomers. Likewise, two different carbons (R, S) 
are present in RRS/SSR and were associated with the two resonances observed in the 17% 
fraction. A similar phenomena was observed in the tetralkylation of the tetraazacyclodecane 
analogue with racemix -bromo acid diesters.(61)  
It should be mention that besides the isomerism in NOTGA ligands coming from the chiral 
carbon in the pendant arms, NOTA-based complexes are chiral depending on the orientation of 
the pendant arms around the metal center (: clockwise or : anticlockwise) and the relative 
puckering of the ethylenediamine subunit chelate rings ( or  conformers).(73, 74) In case 
of gallium, only the enantiomeric ()/() combination has been observed.(73) Therefore, 
each RRR/SSS and RRS/SSR of Ga-NOTGA diastereomeric pair may further exist as the 
enantiomeric combinations ()-RRR/()-SSS or ()-SSS/()-RRR), as well as, 
()-RRS/()-SSR or ()-SSR/()-RRS. Further, X-ray crystallography analysis 
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or computational modeling methods would clarify the actual structure. Nevertheless, both 
diastereomeric ligands provided gallium complexes of high inertness, demonstrated in the apo-
Tf challenge, indicating good retention of the metal inside the complex cavity. 
67Ga radiolabeling was performed at room temperature as previously reported for NOTA 
and its derivatives.(13, 56, 57) The reaction condition allowed assessing the differences in the 
complexation ability of the diastereomeric ligands that otherwise would be suppressed by 
heating. Lower radiochemical yields under acidic conditions were also found by Singh et al. 
(17) when labeling NOTGA and its di-substituted parent, in comparison to the mono-substituted 
and the p-SCN-Bn-NOTA RGD conjugates, possibly due to steric hindrance caused by the three 
substituents. On the other hand, pH 5 was found optimal for labeling NODAGA-RGD with 
68Ga,(75) and a study of the Ga-NOTA formation in acetate solutions found faster reaction rates 
at higher pH.(76) Intriguingly, the RRS/SSR was almost pH-independent from pH 4 to 5.5. A 
hypothesis to account for this observation would be related to the formation mechanism of the 
Ga-NOTA complex and the structural differences between the diastereomers.  
It has been reported that complexation of NOTA and other polyazamycrocycles containing 
pendant arms proceed in two steps. The first step comprises a fast formation of a 
monoprotonated intermediate species in which the metal ion is outside of the macrocyclic cage 
and coordinated to the three peripheric carboxylate oxygen atoms. The ring nitrogen atoms 
remain unbound and the proton would be attached to one of them. In the second step, 
deprotonation takes place followed by migration of the metal to inside the cavity where it also 
becomes coordinated to the nitrogen atoms.(77) Due to electrostatic repulsion between the 
nitrogen’s proton and the metal, removal of the proton is considered to be the rate-determining 
step. (76, 78, 79) It has been proposed this is an OH-catalyzed deprotonation,(76-79) explaining 
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the faster complexation at higher pH. It has also been proposed that the migration of the proton 
from the NH+ group to a carboxylate facilitates the accessibility with respect to OH- ions.(79) In 
either cases, the RRS/SSR conformation might facilitate the access of the OH- ions to the 
nitrogen bound proton or the proton migration to the carboxylate, making the complexation less 
pH dependent.  
To further estimate the differences between the two diastereomers, the binding affinity of 
the two gallium complexes of NOTGA-(TEG-RGD)3 to v3 integrin were estimated by SPR 
assay and it was found that the structural differences in the NOTGA diastereomers presented 
here do not affect the interaction with the targets (Table 2.2). The binding to v3 integrin is 
strongly dependent on the molecular design of multimeric RGD probes. There are two factors 
underneath the enhanced target affinity: enhanced local RGD concentration and multivalency. 
Although the local concentration factor is innate in all multimeric probes, an appropriate 
distance between each two sets of cyclic RGD motifs is required to achieve multivalency.(11, 
80, 81) In this design, the triethylene glycol spacer was inserted to provide a distance between 
the RGD motifs of 37 bonds. According to the previous study,(80) the distance between the two 
cyclic RGD motifs of [67Ga]-NOTGA-(TEG-RGD)3 would be suitable for simultaneous v3 
integrin binding. In addition, Syngh et al. reported that a trimeric RGD linked to NOTGA 
showed enhanced tumor uptake and retention compared with monomeric RGD counterpart, due 
to the multivalent effect partially.(17) From these findings, a combination of multivalency and 
enhanced local RGD concentration might be attributable to higher targeting capabilities of 
[67Ga]-NOTGA-(TEG-RGD)3, reflected in a binding affinity 10 folder higher than the 
monovalent cRGDfK. Thus, both diastereomers might act as trivalent compounds and the 
spatial arrangement of the RGD motifs in each complex would be equivalent with respect to 
binding affinity to v3 integrin.  
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No significant differences were also observed in the biodistribution of the 67Ga labeled 
diastereomers (Tables 2.3 and 2.4, Figure 2.8). Both exhibited rapid blood clearance and renal 
excretion in normal and nude mice bearing U87MG tumors. The high renal uptake was 
consistent with previous studies of other multimeric RGD peptides.(17, 19, 82-84) It was 
reported that endothelial cells of the glomeruli vessels in the kidneys express integrin v3,(85) 
which could partially explain the observation. The presence of three guanidine groups in the 
trivalent RGD conjugate would increase positive charge, which may have facilitated 
reabsorption in proximal renal tubular cells.(19, 20, 85, 86) While both diastereomers exhibited 
similar biodistribution, the elution order of the diastereomers from HPLC (Figure 2.6; RRS/SSR 
followed by RRR/SSS) suggests that a small difference in the lipophilicity between the two may 
be responsible for the slight tendency of the RRR/SSS to be excreted through the intestinal tract, 
though the excretion route is minimal. The similar affinity for integrin v3 along with similar 
pharmacokinetics of the diastereomers resulted in similar tumor accumulation of the two 
compounds (Figure 2.8), yielding SPECT/CT images of high contrast as shown in Figure 2.10.  
The longer-lived 67Ga was used throughout the study. The outcomes of this study would 
also be applicable to the synthesis of 68Ga labeled NOTGA-(TEG-RGD)3. Moreover, given the 
efforts in the processing of generator eluates to reduce metal impurities (1, 10, 56, 87) and the 
sensitivity of PET imaging techniques, superior images of in vivo integrin v3 expression can 
be obtained. Furthermore, NOTGA can be used also for applications with other metal 
radionuclides such as 64Cu, which have been previously incorporated to other NOTA-based 
BFC.(88) 
 
 - 56 - 
 
2.5. Conclusions 
The findings in this study show that the RGD conjugates of both diastereomers presented 
here possess equivalent biological efficacy, and the combined usage of the diastereomic mixture 
would be feasible as far as the present compounds are concerned. It is worth noting that the 
specific properties of a given biomolecule, cell expression levels of the corresponding target 
molecule, presence or absence of pharmacokinetic modifiers might affect the structural 
differences between diastereomers on the ligand-receptor interactions and biodistribution. Since 
the synthesis of diastereomerically pure NOTGA-tBu prochelators has been established, the 
preparation of corresponding conjugates and evaluation of their chemical and biological 
performances still remains important for applying NOTGA to other biomolecules of interest. 
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Chapter 3.                                                                                
General conclusions 
Molecular imaging offers the potential to image non-invasively promising molecular targets; 
shifting the place we look for diseases from tissues and organs to molecular structures and 
mechanisms at cellular and subcellular levels. These molecular targets or more precisely, the 
corresponding targeting molecules need to be part of successful molecular probes to have a 
practical meaning. The outcomes of this thesis, the availability of the positron emitter zinc-63 
and diastereomerically pure molecular designs for 68Ga probes, will undoubtedly contribute to 
the development of novel PET based radiopharmaceuticals for molecular imaging. 
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